Reality Check on Hereditary Angioedema
Market access for Hereditary Angioedema (HAE) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, more than 63% of the covered lives under commercial formularies have utilization management restrictions
- Class Trends: Management of HAE cannot simply be a one-size-fits-all approach, as the condition is variable and patient specific
- Key Findings: Health Plans don't differentiate coverage among provider-administered products, and access to HAE products is not limited at the brand level.
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.